[Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].

Author(s): Prager W, Wissmuller E, Kollhorst B, Boer A, Zschocke I

Affiliation(s): Dermatologikum Hamburg, Stephansplatz 5, Hamburg, Germany. prager@dermatologikum.de

Publication date & source: 2011-05, Hautarzt., 62(5):375-9.

Publication type: English Abstract; Randomized Controlled Trial

BACKGROUND: For the first time, the effectiveness of Xeomin(R), and Dysport(R) in an dose-ratio of 1:3 treating crow's feet (FWS 2-3) was evaluated in a double-blind randomized pilot study. PATIENTS AND METHOD: Xeomin(R) (12 units) was compared to Dysport(R) (36 units) in an intra-individual split-face technique in 22 patients over a period of 4 months. According to the facial-wrinkle-scale (FWS) patients were rated as responders with an improvement of at least 1 point in FWS. RESULTS: One month after treatment significantly more than 80% of patients were rated as responders. The different products proved to be equivalent in response rate and effectiveness with no significant difference after 4 weeks and 4 months in statistical analysis. Surprisingly the decrease in FWS of crows' feet at rest was more pronounced. CONCLUSION: The different botulinum toxin type A formulations proved to be equivalent in effectiveness and tolerability in a dose ratio of 1:3 (Xeomin(R): Dysport(R)) The more pronounced decrease of crow's feet at rest points out the importance of muscle insertion into the skin for the cosmetic result in the periorbital region.